“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...

While they share similarities, there are differences, particularly between the drugs semaglutide and tirzepatide.

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide Apr. 17, 2025 7:30 AM ET Palatin Technologies, Inc. (PTNT) ...

New animal research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide ...

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promise in promoting weight loss and improving metabolic health.

Long-term use of tirzepatide shows sustained and significant weight loss in ... It also reduces appetite by slowing down the time it takes the stomach to empty and interacting with areas in the ...

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide PR Newswire CRANBURY, N.J., April 17, 2025 ...

Consistent with known effects of GLP-1/GIP therapy, over 50% of lost weight was regained within two weeks of stopping treatment in both the tirzepatide and co-administration arms of the study. In ...